Navigation Links
Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
Date:1/19/2009

MONT-SAINT-GUIBERT, Belgium, January 19 /PRNewswire/ --

- New Funds to Drive Clinical Development of C-Cure(R), a Second-Generation Cell-Based Therapy for Heart Failure

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, has raised EUR7.2 million in a successful Series B fund raising round. The new funds, which have come from a range of new and existing investors, will be used to finance the clinical development of the Company's lead product. C-Cure is a unique therapy that allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle. C-Cure holds the promise for a treatment that could fundamentally change the future of heart failure patients, one of the world's largest medical needs. The Company plans to enrol shortly approximately 240 patients in a clinical trial with C-Cure to evaluate its potential in the treatment of heart failure.

Cardio3 BioSciences was founded in 2007 by clinicians from the Cardiovascular Center in Aalst, Belgium with a vision of using a cell-based approach for the treatment of heart disease. The Company is led by a senior management team with extensive experience in developing and commercialising pharmaceutical and medical technologies and leverages proprietary technology developed by researchers from Mayo Clinic, a shareholder in the company. Following the successful B series fund raising, Cardio3 BioSciences has added new investors including the Belgium-based investment group Life Science Research Partners, a Luxemburg-based venture capital firm, Hunza Ventures II that focuses on life sciences, IT and cleantech industries, and Grifols, a Spanish holding company specialising in the pharmaceutical hospital industry. Other new investors were not disclosed.

In parallel with this equity fund
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009).... 25 NuVasive, Inc. (Nas...developing products for minimally disruptive surgi... it will host a conference call on Monday, Novembe...onference call will focus on current issues relati... will include comments from management followed by...
(Date:11/25/2009)...5 Reportlinker.com announces that ...atalogue: ,, Intranasal Drug Delivery - US Mar...r.com/p0164267/Intranasal-Drug-Delivery---US-Marke...rug delivery market is witnessing an expansion of ...entional local therapeutic drugs to the delivery o...
(Date:11/25/2009)...Nov. 25 ChemoCentryx, Inc., anno...he Company,s PROTECT-1 (the Prospective Randomized... of Traficet-EN(TM) (CCX282-B) in patients with mo...ical efficacy with a favorable safety and tolerabi...clinical efficacy in the reduction of disease seve...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 1President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 3Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 1Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 2Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 3Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 4Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 5Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 6Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 7St John 26apos 3Bs Hospital Acquires Latest Technology in Robotic Assisted Surgery 52495 1St John 26apos 3Bs Hospital Acquires Latest Technology in Robotic Assisted Surgery 52495 2St John 26apos 3Bs Hospital Acquires Latest Technology in Robotic Assisted Surgery 52495 3
...., April 15 Pharmacopeia,(Nasdaq: PCOP ), an inn...mall molecule therapeutics, announced today that r...evaluating PS433540, its first-in-class,Dual Actin... a,late-breaking clinical trial at the American So...ientific Meeting and Exposition in New Orleans, Ma...
...15 It is commonly known that many,children get fa...ut as a,person ages, their skin is supposed to cle...of adults who still suffer,from these kinds of fac...with FaceDoctor] says:, "In the western hemispher...but as a bacterial infection.", "If a person with...
Other Medicine Technology:Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540 2Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540 3Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540 4Clinically Proven Treatment Offers Help to Rosacea Sufferers 2
(Date:11/27/2009)...nteractive anatomy education apps from Modality an...sciences learning opportunities for iPhone and iPo...us) November 27, 2009 -- Modality, Inc. and Lipp... Wolters Kluwer Health, today announced the availa...App Store. Clemente’s Anatomy, Rohen’s...
(Date:11/26/2009)...hiomolybdate (TM) has been shown in studies to be ...sease caused by an overload of copper, and certain...le, however, is known about how the drug works at ...estern University researchers now has provided an ...f TM bound to copper-loaded metallochaperones. The...
(Date:11/26/2009)...im of the Live Life Again Center, a practice offer...rowing number of physicians who are taking advant...with individuals who are interested in surgical we...im is utilizing Facebook to share before-and-after...e community. , Dallas, TX...
(Date:11/25/2009)...Newswire-USNewswire/ -- When most people hear the ...hiropractor can also give patients the help they n... which is where your jaw (mandible) contacts/conne...st common symptoms associated with TMJ dysfunction... jaw. But many other symptoms can be caused from ...
(Date:11/25/2009)...ire/ - Sentinelle Medical Inc., a leading manufact...n software launches a suite of new leading edge cl...ng software platform at this year,s Radiological S...hicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A...ty images generated by Sentinelle,s specialized MR...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 4
...m the catastrophic,October 15, 2008 crash of an Ai...filed today on behalf of Robert and Brooke Blockin...h-old daughter Kirstin Reann Blockinger. , Kir...al hit a radio tower and its supporting structure ...
...International Inc. (NYSE: MTD ) today announced ...althcare Conference in San Francisco on Tuesday, J...m. Eastern Time). To hear a live,webcast of the p...en days. , METTLER TOLEDO is a leading global ...
...t than film-screen mammograms, according to a stud...on Cancer Center in Houston, Texas. , The study i...tal screening mammograms and 189 film-screening ma...tes, 7 seconds) for film-screen screening mammogra...
...tional,(NYSE: BAX ), will host a quarterly confe...ncial results on Thursday, January 22, 2009, at 8:... access the call, please dial,866-238-0637 (domest... This call is being webcast by Thomson/CCBN an...
...y of life improved , , TUESDAY, Jan. 6 (He...ds that deep brain stimulation improves both physi...in patients with Parkinson,s disease. , Deep brain...n the Jan. 7 issue of the Journal of the American...
..., WASHINGTON, Jan. 6 Karen Ignagni, President and... statement on new data released by CMS today showi...at the lowest rate in a decade at 6.1 percent in 2... recent peak of 10.7 percent in 2002. CMS also fo...
Other Medicine News:Health News:Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14-Month-Old Girl Killed in October 15th 2008 Medical Evacuation Helicopter Crash Near Aurora, Illinois 2Health News:Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14-Month-Old Girl Killed in October 15th 2008 Medical Evacuation Helicopter Crash Near Aurora, Illinois 3Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 2Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 3Health News:AHIP Statement on National Health Expenditure Data 2
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: